Transformation after Trauma
Our lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
03/14/2023
Transformation after Trauma
Our lives are filled with ups and downs, triumphs and tragedies, success and stress. The question is not whether we…
|
02/28/2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)– The applications are based on results from the Phase 3 CheckMate -76K trial,…
|
|
02/07/2023
Functional Nutrition for Cancer Survivors
In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
|
01/27/2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
|
01/26/2023
A Letter From Our Vice President | January 2023
Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
|
01/26/2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
|
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
01/11/2023
The Grieving Brain: The Science of Love and Loss
Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at…
|
12/23/2022
AIM at Melanoma Earns a Four-Star Rating From Charity Navigator
December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
|
12/19/2022
The Future of Melanoma Treatment: 2023 and Beyond
Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
|
Recent Posts
Mar. 14, 2023
Transformation after Trauma
Feb. 28, 2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Feb. 07, 2023
Functional Nutrition for Cancer Survivors
Jan. 27, 2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
Jan. 26, 2023